Choksi Laboratories delivered robust financial results for the quarter ended March 2026, with net profit rising 11.96% to ₹1.03 crore compared to ₹0.92 crore in the corresponding quarter of the previous year. According to reports from Business Standard, the company's sales grew 12.46% to ₹12.82 crore during the quarter, up from ₹11.40 crore in Q4 FY2025. The strong quarterly performance reflects the company's operational efficiency and market positioning during the March 2026 quarter.
For the full financial year ended March 2026, Choksi Laboratories demonstrated even stronger growth momentum. As reported by Business Standard, net profit surged 28.95% to ₹1.96 crore compared to ₹1.52 crore in the previous year. The company's annual sales increased 10.12% to ₹46.01 crore in FY2026, up from ₹41.78 crore in FY2025. The significant annual profit growth of nearly 29% indicates the company's effective cost management and business expansion strategies throughout the fiscal year.
The company's operating profit margin (OPM) improved to 28.39% in Q4 FY2026 from 30.70% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, the PBDT (Profit Before Depreciation and Tax) increased 19.53% to ₹2.99 crore in Q4 FY2026. The company's PBT (Profit Before Tax) rose 13% to ₹1.10 crore during the quarter, demonstrating consistent operational improvements across key financial metrics.
The strong quarterly and annual performance results reflect Choksi Laboratories' ability to maintain growth momentum despite market challenges. As reported by Business Standard, the company's consistent profit growth across both quarters and the full year indicates effective business strategies and operational efficiency. The significant improvement in annual profit growth compared to quarterly growth suggests the company's ability to scale operations effectively while maintaining profitability metrics throughout the fiscal year.
